StreetInsider.com News Articles

BeiGene, Ltd. (6160:HK) (BGNE) PT Lowered to HK$286.20 at CLSA

Tue, 03 Mar 2026 08:05:47 -0500

CLSA analyst Matthew Yan lowered the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$286.20 (from HK$288.00) while maintaining a Outperform (2) rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Lowered to HK$286.20 at CLSA

Tue, 03 Mar 2026 08:05:47 -0500

CLSA analyst Matthew Yan lowered the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$286.20 (from HK$288.00) while maintaining a Outperform (2) rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Lowered to HK$286.20 at CLSA

Tue, 03 Mar 2026 08:05:47 -0500

CLSA analyst Matthew Yan lowered the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$286.20 (from HK$288.00) while maintaining a Outperform (2) rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Lowered to HK$286.20 at CLSA

Tue, 03 Mar 2026 08:05:47 -0500

CLSA analyst Matthew Yan lowered the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$286.20 (from HK$288.00) while maintaining a Outperform (2) rating.

This Chinese oncology drugmaker is set for catalyst-heavy 2026

Fri, 27 Feb 2026 20:00:00 -0500

Investing.com -- This Chinese oncology drugmaker company closed 2025 with results largely in line with expectations and enters 2026 with a full slate of clinical catalysts.

BeiGene (NASDAQ: BGNE) reported $5.3 billion in revenue for 2025, at the high end of its $5 billion to $5.3 billion guidance range. Fourth-quarter revenue rose 33% year over year to $1.5 billion, with net profit of $67 million. Full-year net income of $287 million came in below expectations due to higher tax expense in the fourth quarter and about $40 million in impairment losses tied to divestiture assets. The company also flagged higher other

This Chinese oncology drugmaker is set for catalyst-heavy 2026

Fri, 27 Feb 2026 20:00:00 -0500

Investing.com -- This Chinese oncology drugmaker company closed 2025 with results largely in line with expectations and enters 2026 with a full slate of clinical catalysts.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$263.69 at Nomura/Instinet

Fri, 13 Feb 2026 07:33:05 -0500

Nomura/Instinet analyst Jialin Zhang raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$263.69 (from HK$217.94) while maintaining a Buy rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$263.69 at Nomura/Instinet

Fri, 13 Feb 2026 07:33:05 -0500

Nomura/Instinet analyst Jialin Zhang raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$263.69 (from HK$217.94) while maintaining a Buy rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$263.69 at Nomura/Instinet

Fri, 13 Feb 2026 07:33:05 -0500

Nomura/Instinet analyst Jialin Zhang raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$263.69 (from HK$217.94) while maintaining a Buy rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$263.69 at Nomura/Instinet

Fri, 13 Feb 2026 07:33:05 -0500

Nomura/Instinet analyst Jialin Zhang raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$263.69 (from HK$217.94) while maintaining a Buy rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$288 at CLSA

Fri, 07 Nov 2025 04:48:21 -0500

CLSA analyst Matthew Yan raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$288.00 (from HK$264.40) while maintaining a Outperform (2) rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$288 at CLSA

Fri, 07 Nov 2025 04:48:21 -0500

CLSA analyst Matthew Yan raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$288.00 (from HK$264.40) while maintaining a Outperform (2) rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$288 at CLSA

Fri, 07 Nov 2025 04:48:21 -0500

CLSA analyst Matthew Yan raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$288.00 (from HK$264.40) while maintaining a Outperform (2) rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$288 at CLSA

Fri, 07 Nov 2025 04:48:21 -0500

CLSA analyst Matthew Yan raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$288.00 (from HK$264.40) while maintaining a Outperform (2) rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$236 at Macquarie

Mon, 08 Sep 2025 05:16:09 -0500

Macquarie analyst Tony Ren raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$236.00 (from HK$204.00) while maintaining a Outperform rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$236 at Macquarie

Mon, 08 Sep 2025 05:16:09 -0500

Macquarie analyst Tony Ren raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$236.00 (from HK$204.00) while maintaining a Outperform rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$236 at Macquarie

Mon, 08 Sep 2025 05:16:09 -0500

Macquarie analyst Tony Ren raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$236.00 (from HK$204.00) while maintaining a Outperform rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$236 at Macquarie

Mon, 08 Sep 2025 05:16:09 -0500

Macquarie analyst Tony Ren raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$236.00 (from HK$204.00) while maintaining a Outperform rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$264.40 at CLSA

Thu, 07 Aug 2025 07:29:23 -0500

CLSA analyst Matthew Yan raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$264.40 (from HK$205.80) while maintaining a Outperform (2) rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$264.40 at CLSA

Thu, 07 Aug 2025 07:29:23 -0500

CLSA analyst Matthew Yan raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$264.40 (from HK$205.80) while maintaining a Outperform (2) rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$264.40 at CLSA

Thu, 07 Aug 2025 07:29:23 -0500

CLSA analyst Matthew Yan raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$264.40 (from HK$205.80) while maintaining a Outperform (2) rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$264.40 at CLSA

Thu, 07 Aug 2025 07:29:23 -0500

CLSA analyst Matthew Yan raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$264.40 (from HK$205.80) while maintaining a Outperform (2) rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$217.94 at Nomura/Instinet

Thu, 07 Aug 2025 06:45:06 -0500

Nomura/Instinet analyst Jialin Zhang raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$217.94 (from HK$209.92) while maintaining a Buy rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$217.94 at Nomura/Instinet

Thu, 07 Aug 2025 06:45:06 -0500

Nomura/Instinet analyst Jialin Zhang raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$217.94 (from HK$209.92) while maintaining a Buy rating.

BeiGene, Ltd. (6160:HK) (BGNE) PT Raised to HK$217.94 at Nomura/Instinet

Thu, 07 Aug 2025 06:45:06 -0500

Nomura/Instinet analyst Jialin Zhang raised the price target on BeiGene, Ltd. (6160:HK) (NASDAQ: BGNE) to HK$217.94 (from HK$209.92) while maintaining a Buy rating.